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ABSTRACT
Objective: To assess the effectiveness of a coach-led
motivational interviewing (MI) intervention in improving
glycaemic control, as well as clinical, psychosocial and
self-care outcomes of individuals with type 2 diabetes
mellitus (T2DM) compared with usual care.
Design: Pragmatic cluster randomised controlled trial
(RCT).
Setting: Community Health Stations (CHSs) in Fengtai
district, Beijing, China.
Participants: Of the 41 randomised CHSs (21
intervention and 20 control), 21 intervention CHSs
(372 participants) and 18 control CHSs (296
participants) started participation.
Intervention: Intervention participants received
telephone and face-to-face MI health coaching in
addition to usual care from their CHS. Control
participants received usual care only. Medical fees were
waived for both groups.
Outcome measures: Outcomes were assessed at
baseline, 6 and 12 months. Primary outcome measure
was glycated haemoglobin (HbA1c). Secondary
outcomes included a suite of anthropometric, blood
pressure (BP), fasting blood, psychosocial and self-
care measures.
Results: At 12 months, no differential treatment effect
was found for HbA1c (adjusted difference 0.02, 95%
CI −0.40 to 0.44, p=0.929), with both treatment and
control groups showing significant improvements.
However, two secondary outcomes: psychological
distress (adjusted difference −2.38, 95% CI −4.64 to
−0.12, p=0.039) and systolic BP (adjusted difference
−3.57, 95% CI −6.08 to −1.05, p=0.005) were robust
outcomes consistent with significant differential
treatment effects, as supported in sensitivity analyses.
Interestingly, in addition to HbA1c, both groups
displayed significant improvements in triglycerides,
LDL cholesterol and HDL cholesterol.
Conclusions: In line with the current Chinese primary
healthcare reform, this study is the first large-scale
cluster RCT to be implemented within real-world CHSs
in China, specifically addressing T2DM. Although a
differential treatment effect was not observed for
HbA1c, numerous outcomes (including HbA1c)
improved in both groups, supporting the establishment
of regular, free clinical health checks for people with
T2DM in China.
Trial registration number: ISRCTN01010526; Pre-
results.
INTRODUCTION
China has become the global leader in the
number of diabetes mellitus (DM) cases, and
this is a critical and costly issue. The
International Diabetes Federation estimated
that, in 2015, there were 109.6 million DM
cases in China, and this number is predicted
to rise to 150.7 million by 2040.1 China’s DM
prevalence is higher in older age groups, in
urban residents and in individuals living in
prosperous regions.1 2 The WHO estimated
DM-related costs to China for 2005–2015 to
be US$558 billion.3 Effective and efﬁcient
DM management and prevention are there-
fore key goals for China.
China is in the midst of major healthcare
reforms intended to build a community-
based primary health system to enable
patients to access health services for basic
and less costly healthcare.4 In order to
manage the large numbers of DM cases, the
Strengths and limitations of this study
▪ This is a rigorous pragmatic cluster randomised
controlled trial implemented in real-world
Community Health Stations (CHSs) in urban
China, utilising existing resources.
▪ The pragmatic nature of this trial meant that data
collection was conducted by multiple data collec-
tors from multiple CHSs and resulted in higher
than anticipated levels of missing data.
▪ Medication use and adherence was not rigor-
ously assessed, however, it can be assumed that
both groups were medicated similarly as per the
Chinese Diabetes Society guideline.
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Chinese government has advocated best practice
medical management.5 6 For T2DM, the guideline
focuses on long-term management, shifting from a
hospital-based model, towards delivery in primary
healthcare settings.7 This approach requires the training
of primary healthcare doctors and nurses in new ways to
support their patients to manage their T2DM.
The use of coach training, behaviour change and coun-
selling approaches for T2DM is widespread in Western
countries. However, these approaches have not been
widely tested in China. Ismail and colleagues’ (2004)—
admittedly now dated—meta-analysis of psychological
interventions for the management of T2DM8 identiﬁed
only two Chinese studies, one utilising cognitive-
behavioural therapy techniques, which found improve-
ments in psychological status,9 and the other using sup-
portive psychotherapy, ﬁnding improvements in glycaemic
control and weight.10 Fu and Dong’s11 meta-analysis of
behavioural and psychological approaches to the manage-
ment of patients with DM with depression or anxiety symp-
toms in China found some evidence that such approaches
improved depressive symptoms and blood glucose control.
A large body of research literature suggests unassisted
behaviour change programmes rarely work effectively in
chronic disease management.12 However, equally, it
cannot be assumed that healthcare workers have the
requisite skills to provide effective support. Most health-
care workers require behaviour change training to assist
patients to achieve their goals. Motivational interviewing
(MI) is a widely used technique in such programmes,
and this was used in the current reported trial.13 Miller
and Rollnick deﬁne MI as “a collaborative, goal-oriented
style of communication with particular attention to the
language of change. It is designed to strengthen per-
sonal motivation for and commitment to a speciﬁc goal
by eliciting and exploring the person’s own reasons for
change within an atmosphere of acceptance and com-
passion” (ref 13, p.29). The exploration and resolution
of ambivalence is a major focus of MI, and it is consid-
ered a particularly useful technique for individuals who
are ambivalent to change a particular behaviour.13
In preparatory work, we piloted health coach training
for doctors and nurses in MI in Fangzhuang, Beijing.
Subsequently, we developed this full trial to test the
effectiveness of the intervention.14 The pilot showed sig-
niﬁcant improvements in glycated haemoglobin
(HbA1c) levels at 6 months.15
In this paper, we report a pragmatic cluster randomised
controlled trial (RCT) of a T2DM management interven-
tion using health coaches in a primary healthcare setting
in Beijing, China. We hypothesised that, compared to
usual care, a structured coach training approach deliv-
ered within a pragmatic study design would enhance the
ability of patients to self-manage T2DM, leading to
improved clinical and psychological outcomes, thus
delaying diabetic complications. In addition, we antici-
pated beneﬁcial impacts on components of metabolic
syndrome and the risk factors for cardiovascular disease.
METHODS
Study design and participants
This pragmatic cluster RCT was implemented from
December 2011 to December 2013, in the Fengtai
District of Beijing, China, which, in 2012, had a popu-
lation of 2.2 million residents.16 A cluster RCT design
was chosen to minimise contamination between the
control and intervention participants that may occur if
participants in the same health service are rando-
mised to different treatment arms. Further, because
the intervention was targeted at changing the behav-
iour of health professionals, once trained, treatment
leakage could have occurred because it would be have
been difﬁcult for them to avoid using the intervention
techniques with control participants. The selection of
a pragmatic trial design, which is undertaken in the
‘real world’ and with usual care,17 also suited the
context of the intervention site, namely Community
Health Stations (CHSs) within a district of Beijing
where preventive care, health management, primary
medical care, rehabilitation, health education and
family planning are offered.18 Additionally, the inten-
tion of this pragmatic trial was to assist in supporting a
decision on whether to deliver the chosen interven-
tion as part of routine care.17
In this instance, CHSs were chosen as the cluster
unit and all government run CHSs within the Fengtai
district were deemed as eligible. This resulted in an
original total cluster sample size of 42 CHSs. Consent
for CHS participation was sought before randomisa-
tion, directly from the Fengtai Health Bureau, which
govern all eligible CHSs. Prior to CHS (cluster) ran-
domisation, an independent person at each participat-
ing CHS identiﬁed eligible participants from the
patient records maintained at each site. Patients with
T2DM were eligible to participate if they were aged
50 years and over, lived in the Fengtai district, had an
established health record and were receiving care at
one of the participating CHSs. Exclusion criteria
included the inability to understand and provide
informed consent (eg, people with cognitive pro-
blems), or a medical condition that precluded adher-
ence to recommendations (eg, end stage cancer). No
further exclusion criteria were implemented due to
the pragmatic nature of this trial. Once generated,
each CHS submitted the participant lists for stratiﬁca-
tion and random sampling.
Sample size estimates were calculated using the ﬁxed
number of clusters available to the current study (k=42).
The intracluster correlation coefﬁcient (ICC) accounts
for the greater similarity of responses of patients within
clusters compared with between clusters, and we applied
an ICC of 0.05 as typical in primary care settings.19 The
effect size for primary outcome, HbA1c, was anticipated
to be 0.32, as determined from a published
meta-analysis.19 Using these parameters, a sample size
calculator for cluster-randomised trials19 estimated a
total sample of n=726 would be required to achieve at
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least 80% power, while maintaining an α of 5% and a
participant attrition rate of 20%.
The above sample size reﬂected an average of 18
patients per CHS (cluster); however, the number of eli-
gible patients varied greatly between CHSs, necessitating
CHSs to be categorised into small and large stations,
with different targets imposed for the numbers of
patients to be recruited. Small CHSs were deﬁned as sta-
tions with less than 80 eligible patients and were asked
to recruit 15 patients, while large stations of over 80
patients were asked to recruit 25 patients per station. As
a result, the total number of patients targeted for
recruitment became 780 (395 intervention group and
385 control group). Figure 1 shows the ﬂow of CHSs
and participants through the trial.
Stratification and randomisation
Clusters (CHSs) were stratiﬁed by geographical location
(outer, central and inner) in order to achieve a balance
of groups. The sociodemographic proﬁle of residents in
Fengtai varies according to geographic location. The
geographic distribution is a combination of longitude
(west, central and east) and radiation from city centre
(2nd, 3rd and 4th ring roads), such that outer Fengtai is
predominantly a regional/rural area; central Fengtai is a
residential suburban area; and inner Fengtai is a devel-
oped urban area. CHSs were randomised into the
control or intervention groups, using block randomisa-
tion. In order to minimise selection bias, this process
was carried out centrally by an independent person and
all CHSs were coded to ensure the randomisation was a
Figure 1 CONSORT flow diagram of Community Health Stations (CHSs) and participants through trial. Of the original 41 CHSs
(21 intervention CHS and 20 control CHS), 2 control CHSs did not follow study protocol with regard to participant recruitment and
baseline data collection, which resulted in incorrect ID allocation, and were therefore removed from analysis. This resulted in a
total of 21 intervention CHSs and 18 control CHSs included in the study analyses.
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blinded process. Prior to CHS randomisation, one CHS
was permanently shut down, resulting in 41 CHSs rando-
mised into the study (21 intervention CHSs and 20
control CHSs). To ensure the required sample size was
still achieved following this closure, one neighbouring
CHS recruited double the participant numbers (ie, 30
instead of 15).
Participants were sampled by computerised random
allocation software that stratiﬁed by gender in order to
achieve balance. The sampling procedure produced an
ordered list of eligible participants; CHS recruiting ofﬁ-
cers systematically invited eligible participants into the
study. If a potential participant was unable to be con-
tacted via telephone on the ﬁrst attempt, a further two
attempts were made before classifying that participant as
‘not contactable’. Once a participant declined participa-
tion or was classiﬁed as not contactable, the recruiting
ofﬁcer moved to the next person on the list. All partici-
pants were provided with an explanatory statement and
consent form, either by mail or in person at their next
CHS visit.
Outcomes
The primary outcome measure was HbA1c. Secondary
clinical outcomes included systolic and diastolic blood
pressure (BP), weight, body mass index (BMI), waist and
hip circumference, as well as fasting blood samples
(fasting plasma glucose, total cholesterol, triglyceride,
high-density lipoprotein (HDL) and low-density lipopro-
tein (LDL)) and were assessed as per the published study
protocol,14 with the exception of LDL cholesterol, which
was measured using a direct method. Additionally, sec-
ondary psychosocial and self-care behaviour outcomes
included: psychological distress (Kessler 10 (K10); score
range 10–50),20 quality of life (QoL) (WHO QoL-BREF;
domain score range 0–100),21 diabetes self-care activities
(SDSCA; score range 0–7, representing number of days/
week)22 and diabetes management self-efﬁcacy
(C-DMSES; score range 0–200).23 See online supplemen-
tary material ﬁle for a full description of the psychosocial
and self-care measures.
All patient level outcomes were assessed at baseline,
and again at 6 and 12 months, during a clinical health
check and an interviewer-administered questionnaire.
All participants were instructed to fast overnight for a
minimum of 8 h, and participant fasting times were
recorded prior to each blood test. Where fasting times
were not sufﬁcient, participants were asked to resched-
ule their appointment. Intervention and control groups
both underwent the same assessments, and all partici-
pants were informed of their clinical results. Participants
who did not present for outcome assessment were fol-
lowed up whenever possible by phone call and asked to
reschedule.
Owing to the pragmatic nature of this trial, data collec-
tors were not blinded to group allocation; however,
laboratory technicians were blinded. Blood samples were
analysed centrally at the Fengtai Center for Disease
Control and Prevention Laboratory, and certiﬁed in
external quality assurance by the National Center for
Clinical Laboratories of China.
Procedure
As recommended for RCTs utilising complex interven-
tions,24 ﬁgure 2 graphically depicts the treatment condi-
tions for intervention as well as for control groups.
Control group participants received usual care from
their CHS as outlined in the Chinese Guideline for
Diabetes Prevention and Management.7 While usual
care is typically expected to vary in pragmatic trials
between patients and providers, and according to institu-
tional policies, the Chinese DM guideline recommends
patients attend quarterly doctor consultations and com-
plete an annual physical examination. The guideline
also includes referral to DM specialists, traditional
Chinese medicine physicians and physiotherapists. In
order to complete the data collection requirements for
the study, increased monitoring that deviated from usual
care recommendations was necessary.
Intervention group participants received a combin-
ation of telephone and face-to-face health coaching in
addition to usual care from their CHS. Health coaching
was performed by experienced clinicians (community
doctors, nurses and psychologists) from each CHS. Prior
to starting the intervention, health coaches completed a
certiﬁed training programme in coach-assisted chronic
disease management. This consisted of a preworkshop
learning phase, which included the study of key con-
cepts in patient-centred communications, health psych-
ology, epidemiology of key targeted illnesses and
conditions, MI and behaviour change, programme evalu-
ation, clinical outcome measurement and the Happy
Life Club intervention protocol.14 This was followed by a
2-day intensive MI workshop that introduced health
coaches to the framework and rationale of MI, and
included the application of MI core skills across the
behaviour change process. To ensure health coaches
were supported in their MI skill development, refresher
workshops were also conducted throughout the inter-
vention. One month after the intervention began, the
coaches received a further half day advanced training
workshop and were contacted every 3 months for
debrieﬁng and feedback.
Health coaches aimed to assist participants in achiev-
ing the treatment targets as outlined in the Chinese
Guideline for Diabetes Prevention and Management,7
with the primary goal of treatment of HbA1c of less
than 7.0%. An intervention manual that utilised existing
local guidelines and recommendations (eg, Dietary
Guidelines for Chinese Residents) was used to guide
health coaches.25 Owing to the pragmatic nature of the
trial, it was anticipated that health coaches would adapt
the intervention manual to their local contexts and, as
such, variation in intervention delivery was expected.
The initial step in each health coaching session was to
set the agenda for the session with the participant. This
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was achieved by asking the participant to identify the
most productive place to start the conversation, that is,
‘What would be helpful to talk about today?’. Once the
participant identiﬁed a key issue for discussion, health
coaches utilised their complex set of MI skills by asses-
sing current behaviour in relation to the issue, and
determined where the participant was in the change
process. Health coaches then guided the conversation
with the ultimate aim of strengthening the participants’
own motivation and commitment for change. By step-
ping out of the expert role into a more guiding, collab-
orative role, health coaches engaged the person in the
process of making signiﬁcant, lasting changes in their
own life.
In the ﬁrst 3 months, participants received two
face-to-face and two telephone coaching sessions per
month. The frequency of sessions decreased over the
12-month intervention period such that in the last
6 months of the intervention, participants received one
face-to-face and one telephone session per month
(ﬁgure 2). This reﬂects the philosophy of the MI
approach whereby, over time, input diminishes as the
participants gain conﬁdence in self-management.
In neither treatment group did participants receive
payment for participation in this study, however, medical
fees (for both, consultation and out-of-pocket pathology
costs) associated with participation in the project were
waived, with associated costs absorbed by the CHSs.
Although China has near universal health insurance
coverage, individuals with T2DM typically incur
out-of-pocket expenses for both, medical (consultation
and pathology costs) and pharmaceutical care.26
Statistical analysis
Descriptive statistics were used to summarise character-
istics of CHSs and participants, with regard to baseline
characteristics and patterns of mean change over time.
To account for clustering and repeated measures col-
lected from participants, we used multilevel mixed
effects models with robust SEs, implemented with
xtmixed, using Stata software (V.12). Random effects
accounted for within-site clustering and within-patient
correlation. Fixed effects included time and intervention
group. The primary analysis examined 6 and 12-month
changes for HbA1c. Secondary analyses included all clin-
ical, psychosocial and self-care continuous outcomes.
Model ﬁt was examined by comparing AIC values.
Models were adjusted for baseline variables of age
group, gender, chronic comorbidity category, time since
T2DM diagnosis, highest education level and residential
address socioeconomic status (categories listed in
tables 1 and 2). ICCs were estimated using one way
analysis of variance. A level of p<0.05 was used to evalu-
ate statistical signiﬁcance of all outcomes.
A missing data analysis was carried out for each
outcome measure and consisted of Little’s MCAR test to
investigate patterns of missingness in variables of group
allocation (intervention/control) and baseline
characteristics as listed in table 3. Sensitivity analyses
were carried out using multiple imputation to account
Figure 2 Graphical depiction of interventions for each treatment condition. MI, motivational interviewing.
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Table 1 Biochemical and clinical outcomes at baseline, and 12 months, by study group
Intervention group Control group Available case analysis
Outcomes N Mean±SD N Mean±SD ICC*
Adjusted difference between
change scores (95% CI)† p Value
Primary outcome
HbA1c (%)
Baseline 359 10.60±2.09 323 10.29±1.71
12 months 295 6.67±1.69 282 6.64±1.59
Mean change from baseline to 12 months (95% CI) −3.86 (−4.16 to −3.56) −3.69 (−3.93 to −3.44) 0.29 0.02 (−0.40 to 0.44) 0.929
Secondary outcomes
Weight (kg)
Baseline 359 70.13±11.71 333 69.68±10.27
12 months 303 70.10±11.74 292 69.51±9.97
Mean change from baseline to 12 months (95% CI) +0.13 (−0.15 to 0.41) +0.32 (0.06 to 0.58) 0.07 −0.09 (−0.58 to 0.40) 0.723
BMI (kg/m2)
Baseline 359 26.23±3.69 333 26.03±3.42
12 months 302 26.22±3.70 292 26.13±3.44
Mean change from baseline to 12 months (95% CI) +0.05 (−0.05 to 0.16) +0.13 (0.03 to 0.22) 0.07 −0.03 (−0.21 to 0.15) 0.734
Waist (cm) men
Baseline 176 93.75±9.29 153 92.82±8.49
12 months 141 92.21±9.36 124 92.85±8.07
Mean change from baseline to 12 months (95% CI) −0.88 (−1.48 to −0.27) +0.56 (−0.04 to 1.15) 0.20 −1.28 (−2.46 to −0.11) 0.032
Waist (cm) women
Baseline 186 88.57±9.57 176 90.68±10.02
12 months 163 88.14±9.16 167 90.90±9.20
Mean change from baseline to 12 months (95% CI) −0.05 (−0.69 to 0.59) +0.32 (−0.33 to 0.97) 0.17 −0.92 (−1.95 to 0.11) 0.080
Hip (cm) men
Baseline 176 102.37±8.69 153 100.23±7.71
12 months 140 102.40±9.08 125 100.54±7.25
Mean change from baseline to 12 months (95% CI) +0.11 (−0.52 to 0.74) +0.92 (0.18 to 1.66) 0.23 −0.03 (−1.34 to 1.29) 0.967
Hip (cm) women
Baseline 186 99.95±8.23 179 102.06±8.81
12 months 162 100.19±8.27 166 102.41±8.78
Mean change from baseline to 12 months (95% CI) +0.31 (−0.32 to 0.94) +0.55 (−0.06 to 1.16) 0.22 −0.36 (−1.58 to 0.85) 0.557
Systolic blood pressure (mm Hg)
Baseline 363 129.03±15.14 334 128.46±14.82
12 months 305 127.79±11.71 292 130.96±12.37
Mean change from baseline to 12 months (95% CI) −1.57 (−3.17 to 0.04) +2.40 (0.89 to 3.91) 0.07 −3.57 (−6.08 to −1.05) 0.005‡
Diastolic blood pressure (mm Hg)
Baseline 363 76.91±9.10 334 76.00±8.64
12 months 305 77.46±7.05 292 76.95±7.23
Mean change from baseline to 12 months (95% CI) +0.17 (−0.72 to 1.06) +1.04 (0.00 to 2.08) 0.13 −0.50 (−2.18 to 1.18) 0.559
Continued
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Table 1 Continued
Intervention group Control group Available case analysis
Outcomes N Mean±SD N Mean±SD ICC*
Adjusted difference between
change scores (95% CI)† p Value
Fasting plasma glucose (mmol/L)
Baseline 367 8.27±2.70 330 8.13±2.74
12 months 297 7.89±2.69 287 7.93±2.57
Mean change from baseline to 12 months (95% CI) −0.41 (−0.73 to −0.09) −0.21 (−0.52 to 0.11) 0.07 −0.11 (−0.64 to 0.42) 0.685
Total cholesterol (mmol/L)
Baseline 363 5.46±1.12 326 5.40±1.19
12 months 300 5.20±1.04 287 5.23±1.23
Mean change from baseline to 12 months (95% CI) −0.27 (−0.40 to −0.14) −0.12 (−0.26 to 0.03) 0.10 −0.10 (−0.35 to 0.16) 0.456
Triglycerides (mmol/L)
Baseline 363 1.91±1.53 326 1.82±1.43
12 months 300 1.63±1.10 287 1.62±1.27
Mean change from baseline to 12 months (95% CI) −0.27 (−0.40 to −0.14) −0.21 (−0.38 to −0.03) – 0.00 (−0.18 to 0.18) 0.990
LDL cholesterol (mmol/L)
Baseline 367 3.70±1.21 329 3.56±1.13
12 months 300 3.34±0.99 286 3.25±1.01
Mean change from baseline to 12 months (95% CI) −0.39 (−0.53 to −0.25) −0.26 (−0.42 to −0.11) 0.29 −0.07 (−0.34 to 0.19) 0.593
HDL cholesterol (mmol/L) men
Baseline 178 1.04±0.31 151 1.08±0.27
12 months 138 1.09±0.33 125 1.11±0.33
Mean change from baseline to 12 months (95% CI) +0.07 (0.01 to 0.13) +0.02 (−0.05 to 0.09) 0.24 0.04 (−0.06 to 0.15) 0.433
HDL cholesterol (mmol/L) women
Baseline 189 1.17±0.35 179 1.17±0.32
12 months 161 1.19±0.35 162 1.25±0.34
Mean change from baseline to 12 months (95% CI) +0.03 (−0.03 to 0.09) +0.09 (0.02 to 0.15) 0.34 0.00 (−0.11 to 0.11) 0.944
*ICC, intracluster correlation coefficients indicated with a ‘−’ were truncated at zero.
†Differences between groups were estimated by multilevel regression, adjusting for clustering and baseline covariates of age group (less than 60 years/60 years or above), gender (male/female),
chronic comorbidity category (diabetes only/diabetes plus other/s), time since diabetes diagnosis (<5 years/5–9 years/10–14 years/15 years or more), education level (primary school or less/
secondary or high school/tertiary education) and residential address socioeconomic status (developed areas/developing areas/less developed areas).
‡Multiple imputation for missing dependent variable values produced the same results.
BMI, body mass index; HbA1c; glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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for missing data and then re-running the analyses. For
each dependent variable with missing data, multiple
imputation using multivariate regression with factors of
intervention group and time produced ﬁve estimates.
RESULTS
Figure 1 depicts the ﬂow of CHSs and participants
through the trial. Of the original 41 randomised CHSs
(21 intervention CHS and 20 control CHS), 2 control
CHSs did not follow study protocol with regard to par-
ticipant recruitment and baseline data collection—
which resulted in incorrect ID allocation—and were
removed from analysis (23 participants). This resulted in
21 intervention and 18 control CHSs included in the
study.
In line with the recommendations for the reporting of
pragmatic trials, numbers of eligible patients and
numbers of those who were contacted and declined
(along with the reasons for non-participation) were
intended to be reported on; however, incomplete
recruitment records in a considerable number of CHSs
prevented this from occurring.
With regard to the 711 participants (intervention:
n=372; control: n=339) who completed baseline data col-
lection, 60 (16.1%) and 43 (12.7%) individuals from the
intervention CHSs and control CHSs, respectively, with-
drew throughout the study period. As a result, 312 and
296 participants in the intervention and control groups,
respectively, were included in the analysis at 12 months
(ﬁgure 1). Missing data analysis showed that dropouts
were missing completely at random (Little’s MCAR test:
χ2=19.4, df=18, p=0.4) when including variables of
primary outcome, group allocation (intervention/
control) and baseline characteristics, as listed in table 3.
Table 3 shows the baseline characteristics of partici-
pants. Mean age was 63.8±8.3 years and there were more
women in the sample (52.7%, 375/711) than men
(47.3%, 336/711). The majority were married (89.8%,
637/709), had received high school education (68.7%,
488/710) and were retired (92.1%, 652/708). The mean
duration of T2DM was 9.8±6.6 years and approximately
one-third of the sample was prescribed insulin at baseline
(31.5%, 223/708). Comorbid chronic conditions were
present for the majority of participants (82.1%, 584/711)
and approximately one-ﬁfth of the sample was classiﬁed
as current smokers (19.3%, 133/688). The intervention
and control groups were similar for all variables at base-
line, and even if statistical differences between groups
were observed then the analysis method could have
accounted for this by adjusting for baseline scores.
Table 1 shows the primary and secondary clinical out-
comes, and table 2 the secondary psychosocial and self-
care outcomes, at baseline and 12 months by study
group (ﬁgure 3A–D summarise the signiﬁcant results).
Outcome data at 6 months are detailed in online supple-
mentary table S1 (clinical data) and online supplemen-
tary table S2 (psychosocial and self-care data).
At 12 months, no differential treatment effect was
found for HbA1c (adjusted difference 0.02, 95% CI
−0.40 to 0.44, p=0.929), with treatment and control
groups both showing signiﬁcant improvements
(Intervention: mean change −3.86, 95% CI −4.16 to
−3.56; Control: mean change −3.69, 95% CI −3.93 to
−3.44). However, treatment effects showing signiﬁcant
improvement in intervention participants compared to
controls were evident in systolic BP (adjusted difference
−3.57, 95% CI −6.08 to −1.05, p=0.005), waist circumfer-
ence in men (adjusted difference −1.28, 95% CI −2.46
to −0.11, p=0.032) and SDSCA-Speciﬁc Diet (adjusted
difference 0.47, 95% CI 0.13 to 0.80, p=0.006.
Psychological distress also signiﬁcantly worsened in the
control group compared to the intervention group
(adjusted difference −2.38, 95% CI −4.64 to −0.12,
p=0.039) (ﬁgure 3A). Other signiﬁcant trends consistent
with increasing weight gain in control participants were
evident in the hip circumference increase in men, and
increases in weight and BMI for men and for women. A
signiﬁcant increase in diastolic BP was also evident in
controls only (mean change +1.04, 95% CI 0.00 to 2.08)
(ﬁgure 3B). Interestingly, both groups also displayed
signiﬁcant improvements at 12 months in triglycerides
(Intervention: mean change −0.27, 95% CI −0.40 to
−0.14; Control: mean change −0.21, 95% CI −0.38
to −0.03); LDL cholesterol (Intervention: mean change
−0.39, 95% CI −0.53 to −0.25; Control: mean change
−0.26, 95% CI −0.42 to −0.11); and HDL cholesterol
(Men—Intervention: mean change +0.07, 95% CI 0.01
to 0.13; Control: mean change +0.02, 95% CI −0.05 to
0.09: Women—Intervention: mean change +0.03, 95%
CI −0.03 to 0.09; Control: mean change +0.09, 95% CI
0.02 to 0.15; ﬁgure 3C).
With regard to psychosocial and self-care outcomes at
12 months, a signiﬁcant improvement was observed
among intervention participants for SDSCA-Blood
Glucose Monitoring (mean change +0.87, 95% CI 0.56
to 1.18) and SDSCA-Foot Care (mean change +0.46,
95% CI 0.09 to 0.83), while control participants dis-
played a signiﬁcant worsening in DM self-efﬁcacy (mean
change −6.78, 95% CI −11.95 to −1.62). The ﬁndings
for QoL domains were variable: a signiﬁcant worsening
was observed among intervention participants for
QoL-Physical (mean change −2.28, 95% CI −3.97 to
−0.58) and among control participants for QoL-Social
Relationship (mean change −2.20, 95% CI −4.25 to
−0.16); while QoL-Psychological signiﬁcantly worsened
among both groups (Intervention: mean change −5.97,
95% CI −8.14 to −3.79; Control: mean change −4.31,
95% CI −6.69 to −1.94) (ﬁgure 3D).
Sensitivity analyses
Sensitivity analyses involved generating ﬁve imputations
for each bit of missing data from the dependent vari-
ables. The numbers of bits of participant data for each
dependent variable that were available for the complete
case analysis are shown in tables 1 and 2. The amount of
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Table 2 Psychosocial and self-care outcomes at baseline, and 12 months, by study group
Intervention group Control group Available case analysis
Outcomes N Mean±SD N Mean±SD ICC*
Adjusted difference between
change scores (95% CI)* p Value
Psychological distress (K10)
Baseline 362 15.31±6.85 328 14.97±6.24
12 months 305 16.16±6.44 288 17.45±8.12
Mean change from baseline to 12 months (95% CI) +0.80 (−0.16 to 1.77) +2.47 (1.39 to 3.55) 0.11 −2.38 (−4.64 to −0.12) 0.039†
Diabetes management self-efficacy (CDMSES)
Baseline 366 159.32±32.99 334 158.96±34.85
12 months 306 156.72±32.68 291 152.75±39.48
Mean change from baseline to 12 months (95% CI) −2.61 (−6.91 to 1.69) −6.78 (−11.95 to −1.62) 0.26 10.71 (−8.72 to 30.13) 0.280
Diabetes self-care (SDSCA)
General diet
Baseline 368 5.37±1.80 337 5.44±1.85
12 months 305 5.34±1.50 287 5.39±1.56
Mean change from baseline to 12 months (95% CI) +0.04 (−0.21 to 0.29) −0.14 (−0.39 to 0.10) 0.22 0.15 (−0.52 to 0.82) 0.665
Specific diet
Baseline 368 4.10±1.51 337 4.37±1.62
12 months 305 4.41±1.24 287 3.93±1.30
Mean change from baseline to 12 months (95% CI) +0.34 (0.14 to 0.55) −0.49 (−0.73 to −0.25) 0.15 0.47 (0.13 to 0.80) 0.006
Exercise
Baseline 369 5.27±2.07 337 5.01±2.13
12 months 305 5.07±1.73 287 4.94±2.11
Mean change from baseline to 12 months (95% CI) −0.20 (−0.46 to 0.07) −0.11 (−0.42 to 0.21) 0.15 −0.12 (−0.78 to 0.54) 0.721
Blood glucose monitoring
Baseline 366 1.46±1.75 336 1.85±1.83
12 months 305 2.45±2.00 287 1.88±1.62
Mean change from baseline to 12 months (95% CI) +0.87 (0.56 to 1.18) +0.01 (−0.24 to 0.27) 0.21 0.43 (−0.26 to 1.11) 0.220
Foot care
Baseline 368 4.50±2.79 337 4.46±2.62
12 months 305 4.90±2.31 287 4.58±2.51
Mean change from baseline to 12 months (95% CI) +0.46 (0.09 to 0.83) +0.07 (−0.30 to 0.44) 0.10 0.55 (−0.30 to 1.39) 0.205
Quality of life (WHOQoL-BREF)
Physical domain
Baseline 368 62.62±12.92 338 63.31±13.99
12 months 306 60.35±12.21 291 61.41±14.45
Mean change from baseline to 12 months (95% CI) −2.28 (−3.97 to −0.58) −1.87 (−3.84 to 0.10) 0.10 1.18 (−3.25 to 5.61) 0.601
Psychological domain
Baseline 368 68.87±14.45 336 67.90±16.18
12 months 306 62.56±15.27 290 63.70±15.50
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missing data for the dependent variables from the 711
participants (372 intervention group and 339 control
group) was as high as 23.8% for the primary outcome of
HbA1c at 6 months; 20.3% for psychological distress at
6 months; 23.5% for waist circumference for men at
12 months; 18.4% for systolic BP at 12 months; and
18.9% for SDSCA-Speciﬁc Diet at 12 months.
In the four signiﬁcant treatment effects seen in the
complete case analyses at 12 months, sensitivity analyses
showed consistent results with two of these: waist circum-
ference and SDSCA-Speciﬁc Diet at 12 months were not
signiﬁcant in the sensitivity analysis. Psychological dis-
tress and systolic BP remained signiﬁcant in the sensitiv-
ity analyses, providing support that these outcomes were
signiﬁcantly better in the intervention group than in
controls.
DISCUSSION
This pragmatic cluster RCT implemented in CHSs in
urban China found no differential treatment effect in
the primary outcome measure, HbA1c, with intervention
and control groups both improving signiﬁcantly.
However, signiﬁcant treatment effects favouring the
intervention group were evident in psychological dis-
tress, systolic BP, waist circumference in men and
SDSCA-Speciﬁc Diet. Two of these outcomes (psycho-
logical distress and systolic BP) were robust outcomes
consistent with signiﬁcant treatment effects, as sup-
ported in sensitivity analyses.
In addition to being statistically signiﬁcant, the greater
psychological distress observed in the control group
compared with that in the intervention group is of clin-
ical signiﬁcance. The shift in the mean score for the
control group at baseline from 14.97±6.24 to 17.45±8.12
at 12 months translates clinically to a shift in the mean
from ‘low risk of psychological distress’ (scores 10–15) to
‘moderate risk of psychological distress’ (16–21).27 This
result may be attributed to control group participants
becoming more aware and knowledgeable about the
degree of their T2DM condition and any comorbidities
simply by participating in the study; and this greater
awareness may have resulted in poorer well-being scores
because control group participants were not given the
same level of psychological support that was provided to
intervention participants. This result may suggest that
health intervention studies with older people in China
may cause additional distress in participants if imple-
mented without accompanying support.
The improvement in systolic BP observed in the inter-
vention group (mean change 1.57 mm Hg) has the
potential, if sustained, for reductions in deaths attribut-
able to cardiovascular disease. In a meta-analysis of 61
prospective observational studies, Lewington et al28
(2002) found that even a 2 mm Hg lower systolic BP
would lead to approximately 10% lower stroke mortality
and approximately 7% lower mortality from ischaemic
heart disease or other vascular causes.
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Other signiﬁcant trends over the 12-month period
consistent with increasing weight gain in control subjects
were evident in the waist and hip circumference
increases in men, and increases in weight and BMI for
men and for women. This suggests that the MI interven-
tion may have been inﬂuential in preventing weight
gain, especially in men, since weight-related measures
had signiﬁcantly increased in control subjects only. A sig-
niﬁcant increase in diastolic BP was also evident in con-
trols only, with the associated consequences being
increased risk of cardiovascular disease.
Although glycaemic control did not differentially
improve, HbA1c in both groups changed signiﬁcantly
and for the better, as did triglycerides, LDL cholesterol
and HDL cholesterol. The mean HbA1c at baseline of
>10% in both groups suggests that participants in our
sample were either not accessing CHSs for T2DM man-
agement or were receiving suboptimal T2DM care prior
to enrolment in this trial. Accurate health service utilisa-
tion records were not able to be obtained for the period
before our study; however, it can be assumed that this
trial served as a catalyst for the revitalisation of primary
care delivery to individuals with T2DM. While the pos-
sible revitalisation may be attributed to a multitude of
practice, participant and study-related factors, the inter-
pretation of the true effect of MI is consequently
limited.
The outcome measures of HbA1c and fasting plasma
glucose typically correlate very reliably with each other
in the management of T2DM, yet this was not the case
in the present trial. Owing to the complex relationship
between the two, we are unable to accurately explain
why the change in HbA1c was not reﬂected in fasting
plasma glucose in this study. We can exclude the possi-
bility of non-fasting blood being sampled as the fasting
duration was documented at each health check.
The signiﬁcant improvement of both treatment
groups for HbA1c and numerous secondary outcomes
may partly be explained by the regular clinical testing
and subsequent feedback to control group participants
following each clinical health check at baseline, 6 and
12 months. The majority of patients with T2DM in
China do not regularly monitor their blood glucose nor
do they attend regular appointments speciﬁcally to
manage their T2DM. According to Xu et al,29 in a con-
venience sample of 201 Chinese adults with T2DM, it
was found that only 4.5% of participants performed self-
monitoring of blood glucose on a daily basis.
Furthermore, a more recent study investigating
treatment-seeking rates among individuals with DM
reported that only 25.8% received treatment for DM
and, of those, only 39.7% had adequate glycaemic
control.2 Additionally, the Diabcare-Asia (China) study
in 2003 found that only 50% of patients with diagnosed
DM had a HbA1c measurement in the previous 12
months,5 despite guidelines recommending HbA1c to
be assessed annually.7 By informing individuals of their
health status in relation to T2DM, it may have prompted
individuals and their CHS care providers to be more
focused on their condition than otherwise expected,
thus altering the ‘usual care’ condition. Additionally, to
maximise participation, control group and intervention
group participants both received free clinical health
checks as part of their participation in the study, further
altering the ‘usual care’ condition. Possible conse-
quences of these alterations to usual care may have been
an improvement in adherence to the T2DM self-care
regimen and increased attendance at CHS appoint-
ments; as well as the start of medication for the treat-
ment of uncontrolled variables. While these
consequences may have contributed to the signiﬁcant
improvement in glycaemic control among control group
participants, intervention participants would equally
have beneﬁted from the feedback of clinical health
checks. One important outcome of the alteration of the
‘usual care’ condition and the result of intervention and
control groups both displaying signiﬁcant improvements
in glycaemic control is that it provides evidence to
support the development of a national T2DM monitor-
ing service that provides free clinical health checks to
patients with T2DM at more regular intervals those cur-
rently recommended.
A further explanation for the signiﬁcant improvement
in HbA1c and numerous secondary outcomes among
both treatment groups is the possible contamination
between CHSs. While every attempt was made to avoid
Table 3 Baseline characteristics of participants by study group
Baseline characteristics Intervention group Control group Total
Participants, n (%): 372 (52.3) 339 (47.7) 711
Age in years, mean±SD 63.7±7.6 64.0±9.0 63.8±8.3
Female, n (%): 191/372 (51.3) 184/339 (54.3) 375/711 (52.7)
Married (including de facto), n (%): 338/371 (91.1) 299/338 (88.5) 637/709 (89.8)
Retired, n (%): 343/370 (92.7) 309/338 (91.4) 652/708 (92.1)
Secondary/high school education, n (%): 266/372 (71.5) 222/338 (65.7) 488/710 (68.7)
Duration of T2DM in years, mean±SD 10.0±6.5 9.6±6.6 9.8±6.6
Currently prescribed insulin, n (%): 124/371 (33.4) 99/337 (29.4) 223/708 (31.5)
Comorbid conditions present, n (%): 316/372 (84.9) 268/339 (79.1) 584/711 (82.1)
Current Smoker, n (%): 68/367 (18.5) 65/321 (20.2) 133/688 (19.3)
T2DM, type 2 diabetes mellitus.
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contamination between CHSs, the study received a con-
siderable amount of media attention throughout the
intervention phase, which may have resulted in partici-
pants and CHS staff altering their usual behaviour.
Additionally, all CHSs participating in this study are
managed and administered by the same government
health bureau, which may also have affected the delivery
of the intervention and control procedures. This was a
pragmatic trial, and the above factors would only have
increased the inherited heterogeneity and dilution of
any treatment effects in the intervention group that are
known to occur in pragmatic trials.30 31
Other than the ﬁndings of our pilot study,32 no cluster
RCTs have assessed the effectiveness of health coaching
based on MI principles for the management of patients
with T2DM in China. Although our pilot study utilised
the same pragmatic design as the present trial, some
notable differences in the results for HbA1c were
Figure 3 Summary of significant study findings. (A) Significant treatment effects shown for the 12-month change scores.
Negative scores indicate better results in the intervention group (except SDSCA-Specific Diet, where positive scores are better).
Waist circumference and SDSCA-specific diet change scores were not significant between treatment and controls in the sensitive
analyses, suggesting that they were not robust outcomes. Not shown are significant changes at 6 months for WHO QOL-BREF
(environment) and SDSCA-general diet (see online supplementary table). (B) Changes in clinical scores at 12 months compared
to baseline. *Significant changes indicating poorer scores in control group only. (C) Changes in clinical scores at 12 months
compared to baseline. *Significant changes indicating better scores. Not shown are significant improvements in fasting plasma
glucose (FPG) and total cholesterol (TC) in the controls at 6 months (see online supplementary table S1). (D) Changes in scores
of psychosocial and self-care measures at 12 months compared to baseline. Positive scores indicate better scores on scales. Not
shown are significant changes in C-DMSES, SDSCA-SpD, SDSCA-Ex, WHO QOL-BREF (physical, psychological, social
relationship) at 6 months (see online supplementary table S2). BMI, body mass index; CDMSES, Chinese Diabetes Management
Self-Efficacy Scale; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SDSCA-SpD,
Summary of Diabetes Self-Care Activities-specific diet; Systolic BP, systolic blood pressure; TG, triglycerides; WHO QoL-BREF,
WHO Quality of Life-BREF.
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observed when comparing trials. In the pilot study, a sig-
niﬁcant improvement in HbA1c from baseline to
6 months was observed in the intervention group only.
Additionally, the baseline HbA1c among both treatment
groups in the pilot study was substantially lower (approxi-
mately 7.0%) than that observed in the present trial
(approximately 10%). One explanation for this variation
may be the difference in the quality of care delivered by
the CHSs, between the pilot and the present trial. The
pilot study was conducted in the Fangzhuang Community
Health Centre, which was the only nationally certiﬁed
centre in Fengtai district at the time of both studies.33 As
such, it is possible that the usual care provided in the
pilot to individuals with T2DM was of higher quality than
that offered by the CHSs in the present trial. Another
possibility is that, in the pilot compared to the full trial,
less ‘leakage’ occurred across the treatment and control
arms of the study. The study was widely reported across
the Chinese media and this may have impacted on treat-
ment ﬁdelity in the control arm of the full study.
Our ﬁndings are consistent with a recent cluster RCT
that similarly found lifestyle counselling based on MI
Figure 3 Continued
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principles did not differentially improve HbA1c, nor did
it have an impact on the majority of secondary outcomes
assessed in our study.34 Some research exists in China
supporting the use of MI for the improvement of gly-
caemic control in patients with T2DM, however, out-
comes were assessed at 6 months and the
methodological quality of studies was variable.35
A number of international traditional RCTs36–38 have
also been published that corroborate the ﬁndings of the
present research, in particular the trial by Rubak et al,36
which found signiﬁcant improvements in metabolic
status within both treatment groups at 12 months with
no difference found when comparing groups. However,
no previous studies have observed improvements in
HbA1c of the same magnitude as the present trial. The
baseline HbA1c values of these studies were substantially
lower (approximately 7%), consequently limiting their
potential for improvement.
The key strength of this study is that it was a pragmatic
trial, speciﬁcally tailored to be implemented in real
world urban Chinese CHSs that utilised existing
resources, hence maximising external validity.
Additionally, the cluster RCT design minimised contam-
ination between CHSs, and the stratiﬁcation and ran-
domisation procedure of both CHSs and participants
minimised selection bias, and increased the generalis-
ability of results to other populations of patients with
T2DM in urban China. Indeed, the baseline demo-
graphic and clinical characteristics of our sample were
similar to those previously observed in individuals with
DM who live in urban and developed regions in China.2
For example, in our sample, there were approximately
similar proportions of males and females; the mean age
of our sample (64 years) was within the second highest
population prevalence age band for DM (slightly higher
population prevalence for ≥70 years); participants were
more likely to have education levels of secondary/high
school or higher, and were also more likely to be over-
weight, and have elevated total cholesterol, LDL choles-
terol and triglyceride levels.
The differential treatment effects in intervention parti-
cipants receiving MI compared with controls is a promis-
ing ﬁnding, and provides evidence for continuing such
interventions. While it is noted that the magnitude of
average improvements was small, this may be attributed
to the pragmatic nature of the trial. The wide eligibility
criteria utilised contributed to a broad population of
individuals with T2DM that more closely resembles that
observed in typical clinical practice; and this variability
between participants may have potentially diluted the
observed treatment effects.30 31 Additionally, the poten-
tial variability of intervention delivery between each
CHS, as well as some possible contamination of the
control CHSs, may have further contributed to the prob-
able dilution of treatment effect. If this study had
adopted a more traditional, explanatory RCT design
under more experimental conditions, it is possible that
the observed treatment effects may have been larger.
A signiﬁcant limitation to this study is that information
on medication use and adherence was not assessed
rigorously enough. While it could be assumed that both
groups would have been medicated similarly as outlined
in the Chinese Guideline for Diabetes Prevention and
Management,7 it was not possible to accurately measure
the impact of any change in medication use throughout
the trial. A further limitation is that intervention ﬁdelity
has not as yet been assessed; therefore it has not been
possible to distinguish between participants with regard
to quality of MI received. All coaching sessions were
audio recorded and a subsequent publication is planned
that will utilise the Motivational Interviewing Treatment
Integrity (MITI) framework to assess intervention integ-
rity. Additionally, the pragmatic nature of this study
meant that data collection was conducted by multiple
data collectors from multiple CHSs. Despite all data col-
lectors being trained according to the data collection
protocol, quality of data varied and this resulted in
higher than anticipated levels of missing data. Further,
the lack of blinding of outcome assessors as well as the
limitations inherent in self-reported data are worth
noting when interpreting the ﬁndings. Another limita-
tion is that only small differential effects in some second-
ary measures were detected, and although small effects
in pragmatic trials are common, since all sources of vari-
ance cannot be controlled, it is possible that they result
from type I errors. Multiple examinations also increase
risk of type I errors.
The results of this pragmatic cluster RCT provides
some evidence for the utility of training health profes-
sionals in the use of MI in the management of patients
with T2DM within Chinese CHSs. We note that the
health professionals in this trial were trained in patient-
centred behavioural counselling and MI, which differs
from their usual, somewhat authoritarian method of
interacting with patients. While the health coaches
embraced the new approach very well, the training com-
prised 20 h and future studies in China could assess how
much training is needed to produce competent MI
health coaches. It is possible that in the current trial the
health coaches had not reached a sufﬁcient standard to
be effective MI counsellors despite improving their
skills. The aforementioned assessment of treatment
integrity will investigate this further.
CONCLUSION
The coaching approach employed in this study is
entirely consistent with China’s primary healthcare
reforms. T2DM is one of China’s most prevalent and
burdensome chronic illnesses, and one that is amenable
to effective community-based primary healthcare inter-
ventions. Differential treatment effects were observed
neither for HbA1c nor for the majority of secondary
outcomes, however, signiﬁcant changes within both
groups with regard to numerous clinical outcomes,
including HbA1c, highlight the advantages of regular,
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free clinical health checks for patients with T2DM. With
a strong focus on self-management and health coach
support, this study has the potential to be adapted to
other chronic diseases, as well as to other regions of
China. Indeed, an extension of the present trial is
planned for implementation in Shenzhen in 2016/17, as
part of the function of the newly formed International
Primary Health Care Research Institute.
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